Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics Third Quarter 2024 Conference Call. Currently all participants are in listen-only mode.
Mersana Therapeutics Inc. (MRSN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 19,364,688 | $36,599,260 | 1.25% | |
| 2. | Citadel Investment Group Ken Griffin | 4,411,555 | $8,337,839 | +61% | 0% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 3,046,782 | $5,758,418 | 0.18% | |
| 4. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 2,223,308 | $4,202,052 | -26% | 0.02% |
| 5. | SilverArc Capital Devesh Gandhi | 1,585,786 | $2,997,136 | -37% | 0.67% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.20 | 14,760 | Director | 8,663,673 | 2022-06-02 | Filing | |
| $3.28 | 80,759 | Director | 8,648,913 | 2022-05-31 | Filing | |
| $3.19 | 75,000 | Director | 8,568,154 | 2022-05-26 | Filing | |
| $3.18 | 90,155 | Director | 8,493,154 | 2022-05-25 | Filing | |
| $3.29 | 100,000 | Director | 8,402,999 | 2022-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.90 | 1,884 | Officer | 54,731 | 2024-10-28 | Filing | |
| $1.96 | 5,598 | Officer | 94,824 | 2024-10-03 | Filing | |
| $2.00 | 8,089 | Officer | 100,422 | 2024-10-02 | Filing | |
| $1.96 | 5,598 | Officer | 63,716 | 2024-10-03 | Filing | |
| $2.00 | 8,089 | Officer | 69,314 | 2024-10-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,328,000 | $26,280,960 | 1.8% | |
| 2. | 8,663,673 | $20,099,721 | 1.92% | |
| 3. | 7,844,282 | $18,198,734 | 0% | |
| 4. | 6,237,588 | $14,471,204 | 0% | |
| 5. | 5,978,327 | $13,869,719 | 2.58% |
News See All
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Call Transcript August 13, 2024Mersana Therapeutics, Inc. misses on earnings expectations.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Mersana Therapeutics First Quarter 2024 Conference Call and Webcast. Currently, all participants are in listen-only mode.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all participants are in listen-only mode.
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Mersana Therapeutics Third Quarter 2023 Conference Call and Webcast. [Operator Instructions]. Please note, this call is being recorded.
5 Best Biotech Penny Stocks to Buy Now
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) ranks 5th in our list of the best biotech penny stocks to buy now according to hedge funds. Ginkgo Bioworks Holdings, Inc.
15 Best Penny Stocks To Buy Now
Investing in penny stocks is risky but if executed correctly gives investors huge opportunities and exposure to multi-baggers of the future.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2022 Conference Call and Webcast. Currently, all participants are in a listen-only mode.
5 Best Biotech Stocks Under $10
In this article, we will look at the 5 best biotech stocks under $10.